ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.748,93
-0,10%
S&P 500
5.308,13
0,09%
Dow Jones
39.806,77
-0,49%
Euro vs US Dollar
1,08665
0,06%
Bitcoin
71.043,89
-0,57%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Marinus Pharmaceuticals Inc (MRNS)

  7. Marinus Pharmaceuticals Inc (MRNS) News

MRNS

Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MRNS
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
17/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
17/05/202413h00Business WireMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramNASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202413h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202413h00Business WireMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/05/202414h00Business WireMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
01/05/202414h00Business WireMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
15/04/202413h00Business WireMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/04/202422h00Business WireMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:MRNSMarinus Pharmaceuticals Inc
27/03/202413h41Business WireMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant ReviewNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202422h14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202422h01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
22/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202413h00Business WireMarinus Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/02/202413h00Business WireMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
16/02/202422h00Business WireMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202422h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202421h07Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202418h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202416h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202415h04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
13/02/202418h13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
19/01/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
19/01/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
19/01/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
19/01/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MRNS

Kürzlich von Ihnen besucht

NASDAQ
GOODO
Gladstone Commercial
LSE
13CP
Akademiska 42
TSX
PREF
Evolve Dividend Stabilit...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten